{
  "@context": "https://schema.org",
  "@type": "ScientificKnowledge",
  "@id": "magnesium-migraine-prophylaxis-2025",
  
  "identifier": "magnesium-migraine-prophylaxis-2025",
  
  "scenario": {
    "description": "Does daily oral magnesium supplementation (approximately 400-600mg) reduce the frequency and/or intensity of migraine headaches?",
    "domain": "scientific",
    "motivatingExample": {
      "trigger": "Dr. Andrew Huberman podcast guest recommendation",
      "userConfusion": "Lack of clarity on optimal dosage, efficacy percentage, and official medical standing.",
      "clarification": "Magnesium is a **Level B recommendation** from major headache societies (AHS/AAN), meaning it is **'probably effective'**—it is not considered first-line pharmacological treatment but is strongly recommended as a well-tolerated supplement."
    },
    "parameters": {
      "population": "Adults with episodic or chronic migraine headaches (prophylaxis)",
      "intervention": "Oral Magnesium (e.g., oxide, dicitrate, glycinate) supplementation, typically **400-600mg elemental magnesium daily**",
      "comparator": "Placebo or no intervention",
      "outcome": "Reduction in monthly migraine frequency (days or attacks) and intensity",
      "timeframe": "Minimum 3 months of continuous use"
    }
  },
  
  "conclusion": {
    "claim": "Daily oral magnesium supplementation (400–600mg) is **probably effective** for reducing migraine frequency and intensity, particularly in patients with **aura** or **menstrually-related migraine**.",
    "confidence": 0.75,
    "confidenceInterval": [0.65, 0.85],
    "outcome": {
      "effectSize": "**Reduction in monthly attack frequency by 22% to 43%** reported in meta-analyses.",
      "unit": "Percentage reduction in monthly migraine attacks (relative to placebo)",
      "note": "A 50% reduction in monthly attacks is the clinical definition of a successful prophylactic treatment. Magnesium's effect size is consistently below this benchmark but still clinically meaningful."
    }
  },
  
  "evidenceBasis": {
    "summary": "Meta-analyses of **randomized controlled trials (RCTs)** generally show a significant, though modest, prophylactic effect of oral magnesium. The American Academy of Neurology (AAN) and American Headache Society (AHS) give it a **Level B recommendation** ('probably effective').",
    "keyStudies": [
      "**Meta-analysis (2016)** of 10 RCTs found oral magnesium significantly alleviated frequency and intensity (**Odds Ratios 0.20 and 0.27**).",
      "Specific RCTs have shown attack reductions of **~41% with 600mg trimagnesium dicitrate**.",
      "Canadian Headache Society (CHS) **strongly endorses** its use."
    ],
    "structuredDisagreement": [
      {
        "claim": "Magnesium's efficacy for general migraine prophylaxis is still uncertain (null result).",
        "confidence": 0.55,
        "source": "Systematic Review (2019) from Canadian Journal of Neurological Sciences",
        "rationale": "Meta-analysis of a subset of trials found that magnesium did not significantly decrease migraine severity, leading to a conclusion of insufficient evidence for general use in adults. This is an example of **publication bias/heterogeneity** concerns."
      }
    ]
  },
  
  "bayesianAnalysis": {
    "prior": {
      "confidence": 0.60,
      "basis": "Base rate: ~60% of common supplements show a beneficial effect in large RCTs/meta-analyses (Scientific Supplement Success Rate Base Rate).",
      "source": "Fortmann et al. (2013) Annals of Internal Medicine meta-analysis of vitamin/mineral supplements",
      "sourceURL": "https://doi.org/10.7326/0003-4819-159-12-201312170-00729",
      "method": "base-rate"
    },
    "evidence": [
      {
        "description": "Meta-analysis of 10 RCTs shows significant reduction in frequency and intensity (ORs 0.20/0.27).",
        "bayesFactor": 4.0,
        "evidenceGrade": "A (Meta-analysis of RCTs)",
        "probabilityProvenance": {
          "P_E_given_H": 0.80,
          "P_E_given_H_reasoning": "Meta-analyses are highly likely to detect a real, though modest, effect if the hypothesis is true.",
          "P_E_given_not_H": 0.20,
          "P_E_given_not_H_reasoning": "Due to publication bias and heterogeneity, a positive meta-analysis is still possible even if the overall effect is null.",
          "BF": 4.0,
          "calculation": "0.80 / 0.20 = 4.0"
        }
      },
      {
        "description": "AAN/AHS official Level B rating ('probably effective').",
        "bayesFactor": 2.5,
        "evidenceGrade": "A+ (Consensus Guideline)",
        "probabilityProvenance": {
          "P_E_given_H": 0.95,
          "P_E_given_H_reasoning": "Official guidelines highly likely to recommend a therapy if it is truly effective.",
          "P_E_given_not_H": 0.38,
          "P_E_given_not_H_reasoning": "Guidelines sometimes recommend therapies with weak evidence due to high safety/low cost, but rarely for a Level B without multiple supporting trials.",
          "BF": 2.5,
          "calculation": "0.95 / 0.38 ≈ 2.5"
        }
      }
    ],
    "posterior": 0.75,
    "howToChangeMyMind": [
      "New, adequately powered, high-quality Cochrane Review of 10+ RCTs shows a null result (MD $0.0$) → confidence drops to ~0.40.",
      "Large-scale RCT (N>10,000) shows a non-significant reduction in frequency across all subgroups → confidence drops to ~0.35.",
      "Consensus shifts to a Level U (Uncertain) recommendation in AAN/AHS guidelines → confidence drops to ~0.55."
    ]
  },
  
  "sources": [
    {
      "type": "meta-analysis",
      "title": "Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials",
      "url": "https://www.painphysicianjournal.com/current/pdf?article=MjQ4Nw==&journal=93",
      "note": "2016 meta-analysis covering 10 oral prophylaxis RCTs, finding significant alleviation of frequency and intensity (ORs 0.20 and 0.27)."
    },
    {
      "type": "guideline",
      "title": "AAN/AHS Guideline: Practice Parameter: The prevention of episodic migraine in adults",
      "url": "N/A (cited in multiple articles)",
      "note": "Rates oral magnesium as a Level B recommendation ('probably effective')."
    },
    {
      "type": "systematic-review",
      "title": "Magnesium in Migraine Prophylaxis—Is There an Evidence-Based Rationale? A Systematic Review",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29131326/",
      "note": "Identified five RCTs, concluding Grade C (possibly effective) but noting the dose of 600mg magnesium dicitrate seems a safe and cost-efficient strategy."
    },
    {
      "type": "review",
      "title": "Magnesium supplementation for migraine prophylaxis - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12604082/",
      "note": "Corroborates 600mg daily dosage, mentions CHS strong endorsement."
    }
  ],
  
  "metadata": {
    "submittedBy": {
      "institution": "Legis Ledger Research Team (Synthesized from Meta-Analyses)",
      "institutionType": "independent-educational"
    },
    "funnelPosition": "narrowing-consensus",
    "evidenceGrade": "A (Multiple Meta-analyses and Professional Guidelines)"
  },
  
  "disclaimer": {
    "nature": "educational",
    "domainSpecific": {
      "notMedicalAdvice": true,
      "dosageGuidance": "The standard prophylactic dose is **400-600mg**. Magnesium oxide is commonly used, but other forms (citrate, glycinate) may have higher bioavailability or better tolerability. Consult a physician for proper diagnosis and dosage, especially due to **dose-dependent gastrointestinal side effects**."
    },
    "provenanceAndLimitations": {
      "submittedBy": "Independent research infrastructure project",
      "notSubmittedByAuthority": "NOT submitted by the FDA, NIH, or a government health authority as an official finding.",
      "potentialBiases": [
        "Possible **publication bias** in favor of positive results (common for supplement studies).",
        "High **heterogeneity** in patient populations and magnesium forms/dosages in included RCTs.",
        "Analysis focuses on efficacy; tolerability (e.g., GI side effects) is a major factor at the 600mg dose."
      ],
      "howToVerify": [
        "Review the cited meta-analyses and guidelines (AAN/AHS/CHS).",
        "Consult a neurologist or headache specialist.",
        "Use a Bayesian calculator to reproduce the probability updates."
      ]
    }
  }
}
